Futura Medical : Results of 2020 Annual General Meeting
June 25, 2020 at 01:04 pm
Share
Date: 24th June 2020
Results of Annual General Meeting
Futura Medical Plc held its Annual General Meeting ("AGM") at STC, 40 Occam Road, Guildford, GU2 7YG earlier today. Allresolutions were voted by way of a poll and passed by shareholders.
The results of the poll are set out below:
Resolution
Votes For ⁱ
%
Votes Against
%
Total Votes
% of ISCVoted
Votes
Withheld ⁱⁱ
1
Receive and adopt Annual Report andaudited financial statements for the yearended 31 December 2019
93,471,224
100
-
0
93,471,224
38.05%
2,342,432
2
Re-election of Jonathan Freeman as a Director
93,459,064
99.99
12,160
0.01
93,471,224
38.05%
2,342,432
3
Re-appointment of Grant Thornton UK LLP asAuditor
93,457,303
99.99
13,921
0.01
93,471,224
38.05%
2,342,432
4
Authorisation for Audit Committee to agree remuneration of Grant Thornton UK LLP
93,457,303
99.99
13,921
0.01
93,471,224
38.05%
2,342,432
5
Authorise the directors of the Company to issue and allot relevant securities (up to 1/3 of the existing issued share capital) pursuant to section 551 of the Companies Act 2006.
93,411,772
99.94
58,952
0.06
93,470,724
38.05%
2,342,932
6
Disapplication of the pre-emption provision of section 561 of the Act in connection withan offer of equity securities by way of aRights Issue or up to an aggregate nominalvalue of £24,563.00 ⁱⁱⁱ
93,377,282
99.9
93,442
0.1
93,470,724
38.05%
2,342,932
7
Disapplication of the pre-emption provision of section 561 of the Act in connection with an offer of equity securities to fund anacquisition or a capital transaction ⁱⁱⁱ
93,367,377
99.89
103,347
0.11
93,470,724
38.05%
2,342,932
8
Adoption of revised Articles of Associationwhich have been amended to allow theCompany to deal with general meetingsmore efficiently ⁱⁱⁱ
93,457,661
99.99
13,563
0.01
93,471,224
38.05%
2,342,432
ⁱ Where shareholders appointed the Chairman as their proxy with discretion as to voting, their votes were cast in favour of the resolution ⁱⁱ A vote withheld is not a vote in law and is not counted towards the votes cast "For" or "Against" a resolution.
ⁱⁱⁱ Special Resolution (75% majority required)
The total voting rights of the Company as at 10.00am on 22 June 2020 (the time by which shareholders wanting to vote at the AGM were required to be entered on the register) was 245,626,926 ordinary shares of 0.02p each. The Company does not hold any shares in treasury
Attachments
Original document
Permalink
Disclaimer
Futura Medical plc published this content on 25 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 June 2020 12:03:06 UTC
Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.